Dr. Mauro Discusses Drug Adherence Among CML Patients

MICHAEL MAURO, MD
Wednesday, February 25, 2015
Michael Mauro, MD, hematologist and leader of the Myeloproliferative Neoplasms Program, Leukemia Service at Memorial Sloan Kettering Cancer Center, explains why some patients with CML don’t adhere to their medication.

Mauro says once the disease has been treated, there are minimal symptoms. However, the therapies used to treat CML can lead to chronic low-grade adverse events. Since CML treatment is indefinite, this can be challenging for patients to deal with, Mauro says.​



Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.